EU and CEPI vaccine funds AUF1 relays Hauser critique

May 19

AUF1 criticizes EU financing of Ebola vaccine development while saying the Commission considers Europe's Bundibugyo-virus risk very low. It reports €73.7 million for CEPI, then a CEPI commitment of up to US$50 million for Moderna's experimental mRNA candidate, with first human tests already underway. It attributes to FPÖ MEP Gerald Hauser the view that this is another pharmaceutical business at European taxpayers' expense. The passage reports commitments and trials, not vaccine efficacy, approval or proof of misuse, and does not date the commitments.

AUF1 reports an EU commitment of €73.7 million to CEPI in an account criticizing Ebola mRNA-vaccine development and contrasting it with the Commission's very-low-Europe-risk assessment. It relays Gerald Hauser's taxpayer-cost criticism. The commitment is not vaccine approval or proof of misuse; the CEPI–Moderna award is a separate occurrence. The broader CEPI funding commitment should not be read as proof that all €73.7 million was earmarked solely for Moderna or Ebola.